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Abstract
Background: Policies for health technologies such as medical devices are essential and contribute to improved
quality of healthcare. The regulation, assessment, and management represent important functions of medical devices.
Insufficiently developed interactions between these functions impact the quality of delivered healthcare. To date
studies lack to analyse these functions in a broad way. The aim of this study is to analyse the regulation, assessment,
and management of orthopaedic medical devices in Mexico and how they shape healthcare.
Methods: This qualitative study included 42 stakeholders involved directly or indirectly in the regulation, assessment,
or management for orthopaedic medical devices in Mexico.
Results: The fragmentation of responsibilities for medical device functions may be a central aspect of our findings
concerning challenges reported by interviewees. Strengthening technovigilance based on improved reporting across
health care institutions emerged as pathway to improve medical device regulation. With regard to improving the
medical device assessment, a comprehensive update of the standard list represents a relevant opportunity. Integrating
advanced quality attributes into procurement processes regarding decision-making, purchasing strategy, and
procurement agent is needed to fostering the management.
Conclusions: This study provides a broad analysis of medical device functions within a health system and highlights in
this specific context how improvements might be achieved. It addresses a broad range of interest groups represented
by policy makers, health service providers, managers and administrators of healthcare facilities, and doctors with an
interest in health technologies. In this paper we highlight important themes that influence outputs and outcomes of
the regulation, assessment, and management and discuss strategies in fostering these areas. To date, the regulation,
assessment, and management of medical devices are rarely analysed in a broad way, even though these functions
importantly contribute to the successful implementation of health technology policies. The quality of delivered
healthcare is influenced by the performance between and within these functions. In Mexico, little discussion
has been raised on challenges of the regulation, assessment, and management of medical devices. Changes
to current processes and practices can improve outputs and outcomes of these functions and positively influence the
quality of delivered healthcare. Stakeholder involvement and commitment is essential to this.
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Background
Policies for health technologies such as medical devices
are essential to assure equitable access to high quality
and affordable devices and their appropriate use and
thus contributing to improved quality of care [1]. The
World Health Organization (WHO) emphasizes the im-
portance of developing and implementing health tech-
nology policies within the context of a national health
plan. WHO indicated that 34% of 145 countries have a
health technology national policy in place that is part of
the national health programme [2]. Mexico is one of
these countries and has established several government
agencies (Table 1) and defined regulations that support
policies for health technologies. This is key to organize
and support, and strengthen important functions for
medical devices. These functions are the regulation, as-
sessment, and management of medical devices and com-
pose important areas of the Medical Device Life-Cycle
(MDLC) (Table 2) and support health care delivery at
different organizational levels within the health system.
Besides the development and implementation of health
technology policies, WHO emphasizes the importance
of the commitment for, and realization of a continuous
improvement plan within and between the areas of the
MDLC in order to strengthen the implementation of na-
tional health technology policies and to contribute to
improved health [1]. This can be achieved when neces-
sary interactions between these areas are established be-
cause of their interdependence. To date, there are
indications of questions regarding different attributes of
the MDLC for orthopaedic high-risk medical devices
(HRMDs) in Mexico and their influence on clinical
practice and thus on the delivered quality of health care
[3–7]. HRMDs are implanted in the human body (such
as a knee joint implant) and are therefore recommended
subject to the highest level of pre-market and post-
market regulation [8]. To date, little is known how these
attributes affect outputs and outcomes of the MDLC
and its meaning for quality of health care. The articles
83, 179 and 180 of the current Medical Device Regula-
tion of Mexico indicate that there are no specific regula-
tions for HRMDs differentiating them from lower risk
medical devices.
The Mexican health system is a complex system with
multiple actors encompassing a public private mix of
hospital providers [9]. The national health care system is
decentralized with planning, management, and regula-
tory authority shared at the federal and state-level
[10, 11]. In Mexico, the different sub-systems of
health care (social security and state-level health care
systems (SESA)) are disconnected and the level of
health care and outcomes between these sub-systems
varies [12]. This leads to a fragmentation of responsi-
bilities with regard to the MDLC areas, which might
affect the ability of policymakers to comprehensively
oversee the MDLC in Mexico.
The aim of the present study is to analyse challenges
of the regulation, assessment, and management of ortho-
paedic medical devices in Mexico and their impact on
outputs and outcomes of the MDLC. Further, we discuss
possible ways forward in fostering the regulation, assess-
ment, and management and their influence on the qual-
ity of delivered health care.
Methods
Our research approach is based on a working framework
(Fig. 1), which is guided by two considerations: (i)
MDLC represents key functions for medical devices and
as a whole it is a functional system contributing to im-
proved health, and (ii) important stakeholders related to
the MDLC exert their influence at the macro level (regu-
lation and policy mechanism), meso level (public health
care institutions and care provider facilities), and micro
level (healthcare professional and patient). The frame-
work guided the data collection and analysis. This re-
search is part of a larger study to investigate the relation
between the regulation, assessment and management of
orthopaedic HRMDs in Mexico and their impact on
clinical procedures.
Study population and recruitment
The study was done in Mexico. We identified and re-
cruited participants for interviews by searching listings
from the governmental offices, public sector, orthopaedic
specialists (public and private sector), organisations,
medical device supplier. We used a maximum variation
sampling [13] to recruit key stakeholder based on three
sample criteria: (1) stakeholders influencing MDLC
areas; [14] stakeholders influencing between MDLC
areas; and [14] stakeholders that have potential to influ-
ence MDLC areas in the future.
Data collection
In total 42 interviews were conducted between April
and May 2016 by the principal investigator and a
research assistant. The principal investigator and a re-
search assistant conducted interviews in Spanish. We
used a file-naming system and anonymized interviewees
by generating a list of archival numbers. We used face-
to-face interviews (n = 39) and phone interviews (n = 3)
(Table 3). All interviews were audio recorded, tran-
scribed, and reviewed again by the principal investigator
with the exception of one interview owing to employer
requirements and we used an interview protocol. The
interview guide (Additional file 1) was previously vali-
dated among a small group of persons familiar with
medical device regulation, assessment, and management.
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Data analysis
To assess views of stakeholders on challenges of and
possible ways forward in fostering the MDLC areas, we
thematically analysed the transcripts [15]. MAXQDA
software (version 11, VERBI GmbH) was used to aid
data management. To describe the views of stakeholders
regarding challenges, first, we closely read each tran-
script. Second, we deductively coded one-third of the
transcripts based on the themes of our conceptual
framework and inductively coded for new themes. Third,
we clustered codes into categories, revised the final list
of codes and categories. Fourth, we systematically ap-
plied coding to all transcripts and drew on important
themes. The principal investigator analysed all primary
data alone, which implies a limitation of validity check.
To integrate the views of stakeholders regarding possible
ways forward in fostering MDLC areas into the discus-
sion of the present study we analysed them in the
Table 1 Principle actors involved in MDLC areas
Stakeholders Main responsibility Relative importance for MDLC areas
Tehno-vigilance Assessment Purchasing
Sub-secretariat for Health System
Integration and Development, SIDSS
• Government agency whose mission is to propose
to the MoH national policies that improve the quality
of social health services; issues the Mexican Official
Norms (NOM)
++ +++ ++(+)
Departments of Sub-secretariat for
Health System Integration and
Development
• General directorate of health planning and development,
DGPD: Governmental organization and unit under the
authority of the SIDSS whose mission is to steer the
strengthening of health services among policy makers,
and giving guidance to improve health services sustainable
and cultural based on populations’ needs.
• General directorate of quality and education, DGCE:
Governmental organization and unit under the authority
of the SIDSS whose mission is to ensure that the quality
and safety of health services, including human resources
of the health sector and the regulatory environment of
social health supplies is aligned with national policies.
++ +++ ++(+)
General Council of Health, CSG • Sanitary authority directly accountable to the President
• Council whose mission it is to strengthen the governance
and the articulation of the National System of Health.
Founded: 1917
• Publishes the standard list of Health Supplies
• Holds the Inter-institutional Commission of the standard
list for Health Supplies whose mission is to manage the
approved technologies in the standard list for Health Supplies
• Auditing of hospitals with regards to quality standards
(certification process)
++ ++(+) +
Federal Commission for the
Protection against Sanitary Risks,
COFEPRIS
• Decentralized organ of the MoH whose mission is to
protect the population against medical risks derived from
the introduction of new medical drugs, medical devices
and other health inputs. Founded: 2002
• Sanitary Authorization Commission whose mission is the
market approval of medical products and technologies.
• Technovigilance department whose mission is to implement
and realize post-market surveillance.
• Support function of “Sanitary Authorization Commission”
whose mission is to provide technovigilance reports for
the renovation of market approval.
+++ ++ +
National Centre for Health
Technology Excellence, CENETEC
• Governmental organization and unit under the scope of
the SIDSS whose mission is to contribute to the development
and governance of the National Health System in Mexico
based on: Health Technology Assessments, Supervision of
medical equipment, Telemedicine, Clinical guidelines.
Founded: 2004
• WHO collaborating centre.
++ ++(+) ++(+)
Sub-systems: Centralized and
decentralized health services
• Functionary with national responsibilities within the
sub-system; director of healthcare facility; procurement
agent
+++ ++(+) +++
• Functionary with local responsibility: Head of orthopaedic
department
- +(+) ++
+++ strong relation ++ moderate relation + low relation - no relation
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context of the key findings, the findings of our previous
studies and the results of our background research on
current medical devices reforms and policies.
Results
The results of this study are structured along the areas
regulation, assessment, and management and summa-
rized by their importance in Table 4. Illustrative quota-
tions are presented in Table 5.
Area of regulation: Reporting of adverse events and
complications during clinical practice
There was some degree of consensus among inter-
viewees that technovigilance activities (post-market sur-
veillance of approved medical devices) should be
strengthened across all levels of health-care delivery, but
mainly at the meso level (health care institutions).
Further, these activities may contribute to a wider scope
of decision-making such as purchasing decisions. In
Table 2 Important outputs and outcomes of the MDLC areas
Areas Description Outputs Outcomes
Regulation Safety and efficacy are in the focus of this phase to
aim population safety. Key elements are performing
testing, safety assessment & post-market reporting
using criteria of safety and quality standards.
Mandatory compliance Assuring minimal standards of quality
Assessment Serving the population is in the focus of this phase
to aim population health. Key elements are systematic
analysis and critical review using epidemiology and
evidence data.
Recommendations on highly
complex technologies
Responsiveness and maximization
of clinical outcomes and cost-
effectiveness
Management Health service providers are in the focus of this phase.
Key element is the operational management of
technology life-cycle using needs analysis and reliable
device availability for clinical use.
Operational rules and guidance
for all medical devices
Improved health delivery; sustainable
availability of high-quality and safe
devices
Source: Adapted from WHO (WHO, 2011a, WHO, 2011b)
Systematic analysis and critical review using epidemiological 
Output: 
Recommendations, e.g. 
National Standard List
Outcome: 
Responsiveness and 
maximization of clinical 
outcomes
Macro level 
Normative & policy mechanism
Meso level
Public & private institutions
Micro level
Healthcare professional & patient
Regulation
Management 
Performing testing, safety assessment & post-market reporting
using safety and quality standards
Output: 
Mandatory compliance
Outcome: 
Risk mitigation and 
prevention of harm
Operational management of technology using needs analysis, 
Output: 
Operational rules and 
guidance
Outcome: 
Improved health care 
delivery
Supplier
Assessment 
Fig. 1 Research framework
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Mexico, monitoring activities for HRMD safety and
performance take place under the supervision of the
Technovigilance department of the Federal Commission
for the Protection against Sanitary Risks, which relies on
the reporting of health care institutions. Interviewees
noted that the reporting of health care institutions is
sub-optimal. The federal Technovigilance department
encompasses decentralized departments of the SESA
and the responsible technovigilance actors at the social
security institutions. Few interviewees thought that they
did not see significant advances in technovigilance activ-
ities since its introduction in 2013 and thought that it
was not implemented sufficiently. They noted that tech-
novigilance often only exists on paper rather than in
daily practice. Interviewees provided different reasons
for this. Many interviewees thought that monitoring the
safety and performance of HRMDs was insufficiently de-
veloped for a long time. Some interviewees from the
macro level noted that a major difficulty to improve
technovigilance was to coordinate the different sub-
systems of the Mexican health system. They stated that
the commitment of users and suppliers to inform tech-
novigilance officers about adverse events and incidents
is irregular and activities at the meso level provide insuf-
ficient guidance to HRMD users.
Intra-operative complications are negative outcomes
of using HRMDs during surgery and accompanying ser-
vices such as instruments, implant sets, surgical tech-
nique, or technical assistance of supplier during surgery.
Some interviewees stated that users report intra-
operative complications to procurement administrators
so that they can be managed in the context of service
and delivery contract duties. But some noted as well that
managing information about these complications is es-
sential as these failures may influence medical outcomes
in the long-term, considering their nature and frequency.
Further, few interviewees noted that the awareness of
the involved stakeholders about how reporting can con-
tribute to decision-making at the meso and macro levels
is low. Some interviewees thought that establishing an
effective reporting system and infrastructure may
Table 3 Respondent characteristics
Stakeholder group Participant Male Higher hierarchical level
N (%) N (%) N (%)
Group 1 (macro level) 24 (57) 16 (63) 18 (58)
(i) Having direct relation to MDLC areas 11 (46) 5 (45) 8 (73)
CSG, MoH, General directorates 4 (36) 3 (75) 4 (100)
COFEPRIS, CENETEC 6 (55) 2 (33) 3 (50)
International organization or experts for
Mexican health system
1 (9) 0 (0) 1 (100)
(ii) Indirect relation to MDLC areas 13 (54) 11 (85) 10 (77)
MoH, General directorates 3 (23) 2 (67) 2 (67)
National institutes, organizations, or experts
concerned with public health, quality of
health services, or patient safety
8 (62) 8 (100) 6 (75)
International organization or experts for
Mexican health system
2 (15) 1 (50) 2 (100)
Group 2 (meso level)a 5 (12) 2 (40) 4 (80)
Financing/provision of health services 3 (60) 1 (33) 3 (100)
Quality of health services 2 (40) 1 (50) 1 (50)
Group 3 (micro level)a 9 (21) 7 (78) 2 (22)
Orthopaedic specialists 9 (21) 7 (78) 2 (22)
Group 4 (supplier) 4 (10) 3 (75) 4 (100)
Medical device industry association 1 (25) 0 (0) 1 (100)
Medical device supplier 3 (75) 3 (100) 3 (100)
Total 42 (100) 28 (67) 28 (67)
aSocial security institutes and State-level health care systems
Table 4 Frequency of discussed themes regarding challenges in
organizational practice
MDLC area Total Group 1 Group 2 Group 3 Group 4
Regulation ++(+) ++(+) ++(+) ++ +(+)
Assessment ++(+) ++(+) + ++ +++
Management ++(+) ++ ++ +++ +++
+ low intensity; ++ some intensity; +++ high intensity
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contribute to the strengthening of the evidence of intra-
operative complications, which is contributing to
technovigilance.
Area of assessment: Decisions about the eligibility of HRMDs
Many interviewees indicated that the eligibility of ortho-
paedic HRMDs was not regulated thoroughly enough.
Some interviewees noted that the current version of the
standard list for orthopaedic and osteosynthesis medical
devices still included several obsolete technologies or
misleading descriptions. They noted that a major diffi-
culty is that, by law, these changes to the standard list
require formal modification requests from, e.g., a social
security institution or a medical device supplier. Neither
the inter-institutional committee nor the General Council
of Health can implement such changes independently.
Some interviewees thought that solving these problems of
eligibility requires, among else, strong governance and im-
provement plans. They noted that updating the standard
list is important, but only as a prerequisite rather than as
a sustainable step in improving the post-market regulation
of HRMD eligibility. Despite the national standard list
(macro level), each public health institution manages its
own standard list for health supplies (meso level). Few in-
terviewees thought that it was necessary to unify these
standard lists into one single standard list.
Area of management: Procurement decision-making,
purchasing strategy, procurement agent competencies
In Mexico, decision-making is strongly guided by con-
formity checks of HRMD specifications (e.g. material,
mechanical characteristics, dimensions) and lowest-price
offers [3–5]. Many interviewees thought that the applied
procurement regulations and practices in use have not
advanced over the past years. Some interviewees noted
that decision makers had difficulties understanding dif-
ferences between medical device brands in terms of their
clinical performances (e.g. implant survival rate, primary
stability of implant, implantation based on surgical tech-
nique). They thought that improved and systematic risk
assessment of HRMDs might elucidate risks in a wider
scope with the potential to lead to a more thorough use
of public budgets, such as Health Technology Assess-
ments (HTA) at hospital level. They noted that medical
devices are currently not assessed sufficiently such as
implant survival rate. Some interviewees thought that in-
tegrating aspects of quality more thoroughly could con-
tribute to the changing of decision-making criteria.
Some interviewees thought that solving deficiencies of
specific purchasing strategies could positively influence
procurement outcomes and the quality of services pro-
vided, respectively. They noted that nowadays outcomes
are affected by sub-optimal supplier performance; sup-
pliers are often unable to respond timely with material
and technical support to contract assignments because
they are often contracted shortly before the contract
period started. Many interviewees noted that the in-
creasing use of the bundling of services through Servi-
cios integrales requires more quality control. A Servicio
integral encompasses a range of disposable and non-
disposable medical products used for surgery and merges
them into one supplier service. Some interviewees noted
Table 5 Quotations of interviewees
Quotations Stakeholder group
Area of regulation: Reporting culture of adverse
events and complications during clinical practice
„Often they don’t know that there is a regulation
for technovigilance.“
Macro level
„… we explained to the health professionals that
finally they are the ones who complain about a
product that fails and that the product does not
provide the required results. However, me as
authority how can I take notice about that
< complaints > if they < end-users > dont make
notifications, if they don't report failures than I
cannot find it out and if I don't find it out I
cannot react, if I dont react the things stay as
they are.“
Macro level
„… not only the bad quality of the materials but
also the bad service which they provide for
technical assistance… This type of complaint
converts into an internal report and stays there,
I am sorry that I have to say that.“
Micro level
„… do you believe that the authorities of the
institutions don't know the needs that exist?“
Macro level
Area of assessment: Decisions about the
eligibility of HRMDs
„… we noticed the extremely poor culture of
science that was present in the area of technology
assessment.“
Macro level
„As a result of poor regulation every buys what he
wants and we complain about lots of things…“
Meso level
„A lot of people said as well that we should skip
the institutional standard lists.“
Macro level
Area of assessment: Decisions about the
eligibility of HRMDs
„I believe that the first error of the pseudo
transparency of implant procurement is that they
buy at the lowest price.“
Macro level
“It's incredible that a surgery has to be cancelled
because the supplier did not arrive with the
material … Which economic penalty can
compensate this damage to the patient…”
Micro level
“… a serious problem of the servicio integral is
that they decide which brands they include in
their service packages … Cheaper products so
that they make more profit.”
Supplier
„… there are constant changes, when a new
person comes sometimes he dosent has sufficient
preparation to realize a tender.“
Micro level
„… the procurement agent knows the standard
list but little about the basics of a joint implant.“
Supplier
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that this facilitates the public sectors’ administrative pro-
cesses, but it also removes the procurement administra-
tors’ control of the final selection of the orthopaedic
HRMD brand.
Some interviewees explained that decision makers
underestimated the role played by the procurement
agent who is concerned with administrative tasks and
processes to support needs assessment or analysing sup-
plier offers. They thought that procurement agents
should have minimal professional skills underlined by
specific certificates so that they were able to understand
clinical needs better and to not affect negatively procure-
ment results. Many noted that administrators often have
difficulty understanding the clinical needs of users and
underestimate the consequences of their decisions about
clinical procedures. Some of the interviewees mentioned
the importance of continuous training; it could contrib-
ute to changing a purely administrative passive support
into a more integrated service function. Until now, little
attention has been paid to the continuous education of
procurement agents.
Discussion
Interview participants identified important challenges
in relation with the MDLC areas in Mexico (affecting
policy outputs and outcomes), which might influence
the quality of care. With regard to regulation, report-
ing of adverse events was perceived as the most im-
portant challenge; assessment is challenged by several
obsolete or wrongly described technologies in the
standard list for orthopaedic and osteosynthesis prod-
ucts; while integrating advanced quality attributes into
procurement processes was a mayor issue raised re-
garding the area of management. According to inter-
viewees, subjacent to these challenges is the
fragmentation of responsibilities with regard to the
MDLC areas and the disconnection of the several
sub-systems of health care. Overall we found that this
causes a lack to support well-integrated MDLC areas
and translates into sub-standard outputs and out-
comes. In consequence the multiple actors have diffi-
culties to improve the quality of delivered health care.
Possible ways forward in fostering the regulation, as-
sessment, and management of medical devices in
Mexico are:
 Regulation: Strengthening technovigilance
 Assessment: Updating the Standard list for
orthopaedic and ostheosynthesis medical devices
 Management: Introducing a decision-making guidance
with focus on quality attributes for decision-making,
purchasing strategy, and procurement agent
competencies
We found that strengthening technovigilance can po-
tentially improve outputs and outcomes of the regulation
in the following ways: It can influence the compliance of
involved stakeholders (e.g. for post-market reporting) and
contribute to improved quality. To strengthen technovigi-
lance three aspects may be considered: (i) including tech-
novigilance tasks in the requirement catalogue of hospital
certifications, (ii) fostering inter-institutional technovigi-
lance guidelines, and (iii) implementing a technovigilance
code of conduct (for hospital providers, health-care
workers and suppliers). Further, in the literature we found
that countries having a well-functioning post-market sur-
veillance system complement their regulatory tasks by in-
tegrating specific approaches into the regulators’ work to
evaluate health technologies or define benchmarks for
quality standards [16, 17].
We found that introducing a guidance focusing on
quality attributes can improve outputs and outcomes of
the assessment and management in the following ways:
It can enrich decision-making by knowledge about clin-
ical longterm performance of medical devices, and im-
prove clinical outcomes and cost-effectiveness. Further,
it can influence operational rules and guidance for
orthopaedic HRMDs and contribute to improved quality
of delivered of health care. To introduce stronger quality
attributes the following aspects may be considered: (i)
introducing quality benchmarks for orthopaedic proce-
dures (e.g. survival rate requirements) and establishing
survival rate expectations for new listed technologies;
and (ii) Introducing HTA at the level of hospitals or pur-
chasing groups that allow to integrate a risk assessment
of orthopaedic HRMDs into decision-making. Further,
we found that in the United Kingdom the National
Institute for Health and Care Excellence defines recom-
mendations including benchmarks, e.g., for the quality
of hip prostheses, as “the new joint should work well in
at least 95% of hip replacements over 10 years, instead
of the current 90%” [18]. These recommendations con-
tribute to the maximization of clinical outcomes and cost-
effectiveness and can be reflected in risk assessments for
orthopaedic HRMDs [19, 20]. Understanding the role
played by decision makers concerning the absence of
high-quality data is an important insight into procurement
activities such as purchase and supply [21, 22].
We found that enhancing competencies of procure-
ment agents can improve outputs and outcomes of the
management phase in the following ways: It can influ-
ence operational rules and guidance for orthopaedic
HRMDs and contribute to improved health care deliv-
ery. To enhance competencies of procurement agents
the following aspects may be considered: (i) Updating
requirements for core competencies needed for procure-
ment agents, and (ii) integrating procurement agents
into evaluation tasks of outcomes of applied purchasing
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strategies such as Integral Services. Further, in other
countries the orthopaedic specialist still has high
decision-making autonomy, which alleviates some re-
sponsibility from the procurement agent. Thus we had
difficulties to find examples emphasizing the aspect of
enhancing competencies of procurement agents.
This study highlights important findings in a national
context. However, some issues identified by the present
study do emerge in a similar way in other health systems
as well. For instance, the Swiss healthcare system is
characterized by a decentralized structure with large
decision-spaces at cantonal (regional) level. However, the
healthcare legislative allows for initiatives and pro-
grammes that benefit the whole of the country so that the
fragmentation of responsibilities regarding the MDLC
areas is contained. For instance, Switzerland did face simi-
lar problems as Mexico relating to post-market surveil-
lance regarding the level of clinical long-term data
available for orthopaedic medical devices. As a solution to
this a national arthroplasty registry, which is overseen by
the National Association for Quality in healthcare
facilities, was introduced. This was only possible by sub-
stantial commitment of the different parties concerned by
the registry such as national and local policy makers, in-
surances, the associations of orthopaedic surgeons and the
medical device industry. The Mexican healthcare system
is characterized by various sub-systems of health service
provision. The healthcare legislative limits the authority of
the MoH to establish initiatives or programmes regarding
medical devices that could benefit the whole sector. For
instance, the social security institutes apply their own reg-
ulations for the assessment and management of medical
devices. We found that this fragmentation of responsibil-
ities influences the ability of policy makers to carry for-
ward promising ways to improve outputs and outcomes of
the MDLC areas. However, the relation between the MoH
and sub-systems is in a transition and some recent ad-
vances demonstrate that [12, 23, 24]. For instance, policy
makers agreed on an information technology system that
enables them to consolidate relevant key data across the
different sub-systems at federal level. This system that is
supported by all sub-systems is called the National System
of Basic Information in Healthcare (SINBA) [26]. It is
under the supervision of the National Department for In-
formation in Health of the Ministry of Health and can sig-
nificantly contribute to improvement. SINBA is still in
progress but expected to be launched by end of 2017. It
represents an information strategy for capturing and con-
solidating data across the different sub-systems. As next
steps for the policy making process in Mexico we recom-
mend to take into account that the integration of stake-
holders such as the National Academy for Medicine, the
associations of orthopaedic specialists, and the associa-
tions of the medical device industry is important as they
can contribute to the establishment of initiatives and pro-
grammes to improve the MDLC areas, and help to partially
overcome the fragmentation of responsibilities. An import-
ant next step is the strengthening of Technovigilance.
Limitations of the study
For this study, we used non-random sampling, which
does not necessarily guarantee the sample being repre-
sentative for the population of person involved in the
regulation, assessment, and management of medical de-
vices in Mexico. However, this study includes 42 stake-
holders working in the field of regulation, assessment,
management or clinical practice. Thus it covers different
groups of stakeholders in terms of expertise. We were
not granted permission to include employees of the
Mexican Institute of Social Security, which is the largest
social security institution in Mexico, because of its re-
search study approval policies. Further, the sampling is
based on a maximum variation strategy and may consti-
tute a selection bias. The interpretation of the findings
that served to define possible ways forward to fostering
the regulation, assessment, and management of ortho-
paedic medical devices is a subjective process.
Conclusions
This study provides a broad analysis of medical device
functions within a health system and highlights in this
specific context how improvements might be achieved. It
addresses a broad range of interest groups represented by
policy makers, health service providers, managers and ad-
ministrators of healthcare facilities, and doctors with an
interest in health technologies. In this paper we highlight
important themes that influence outputs and outcomes of
the regulation, assessment, and management and discuss
strategies in fostering these areas. To date, the regulation,
assessment, and management of medical devices are rarely
analysed in a broad way, even though these functions im-
portantly contribute to the successful implementation of
health technology policies. The quality of delivered health-
care is influenced by the performance between and within
these functions. In Mexico, little discussion has been
raised on challenges of the regulation, assessment, and
management of medical devices. Changes to current pro-
cesses and practices can improve outputs and outcomes
of these functions and positively influence the quality of
delivered healthcare. Stakeholder involvement and com-
mitment is essential to this.
To overcome the impact of the fragmentation in the
Mexican health system, policy makers could orientate on
what other countries with a similar complex health sector
are doing to improve outputs and outcomes of the MDLC
such as the United States, Germany, or Switzerland. An
important advance is that the Ministry of Health is
developing a new policy that targets to strengthen
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technovigilance across all sub-systems. This is a promising
way forward in fostering the regulation and to fully engage
all stakeholders. This study may contribute to show to
policy makers additional ways forward in fostering the
regulation, assessment, and management towards im-
proved quality of delivered health care.
Additional file
Additional file 1: Interview Guide. (DOCX 117 kb)
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